financetom
Business
financetom
/
Business
/
Deere's Fiscal Q4 Likely to be Weakest in Terms of Pricing, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Deere's Fiscal Q4 Likely to be Weakest in Terms of Pricing, Oppenheimer Says
Nov 19, 2024 9:15 PM

03:12 PM EST, 11/18/2024 (MT Newswires) -- Deere's (DE) fiscal Q4 is likely to be its weakest in terms of pricing as the company leaned into incentives to help move dealers' excess used inventory, Oppenheimer said in a note emailed Monday.

While Deere's efforts would likely place it in the "best inventory position relative to peers," the company is still likely to face "pockets of continued underproduction" in calendar 2025, Oppenheimer said.

Deere will release its fiscal Q4 results on Thursday.

Meanwhile, Deere is also expected to set conservative initial estimates for fiscal 2025 amid limited order coverage and ongoing destocking, according to the firm.

Oppenheimer said the company's stock price could fall in the low-$300 range if Deere's guidance suggests fiscal 2025 earnings of $18 per share. The firm said it would be "constructive" if the guidance implied a $20 per share midpoint instead.

"While we are not giving an 'all clear' on the cycle, we do see support for [Deere] to inflect to positive earnings growth in FY2025 as destocking headwinds abate," Oppenheimer wrote.

Oppenheimer has an outperform rating on Deere's stock.

Price: 404.97, Change: +6.02, Percent Change: +1.51

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
Oct 21, 2024
Sanofi SA ( SNY ) and private equity Clayton Dubilier & Rice (CD&R) have finally entered into exclusive negotiations to potentially sell and purchase a 50% controlling stake in Opella, Sanofi’s consumer health unit.   The new step in Opella’s journey paves the way for creating a standalone player in consumer healthcare while supporting Sanofi’s strategy and increased focus on innovative...
Aura Biosciences Insider Sold Shares Worth $300,839, According to a Recent SEC Filing
Aura Biosciences Insider Sold Shares Worth $300,839, According to a Recent SEC Filing
Oct 21, 2024
08:45 AM EDT, 10/21/2024 (MT Newswires) -- Elisabet de los Pinos, Director, President and Chief Executive Officer, on October 18, 2024, sold 24,992 shares in Aura Biosciences ( AURA ) for $300,839. Following the Form 4 filing with the SEC, Elisabet de los Pinos has control over a total of 461,259 shares of the company, with 329,847 shares held directly...
Regenxbio Reports 97% Reduction in Injection Need for Wet AMD; Shares Rise Pre-Bell
Regenxbio Reports 97% Reduction in Injection Need for Wet AMD; Shares Rise Pre-Bell
Oct 21, 2024
09:08 AM EDT, 10/21/2024 (MT Newswires) -- Regenxbio ( RGNX ) reported Monday a 97% reduction in anti-VEGF injections at nine months in a Phase II study of ABBV-RGX-314 for wet age-related macular degeneration, or AMD. In the subretinal treatment of the second eye, 78% of patients remained injection-free, the company said. Visual acuity and retinal thickness were maintained, with...
Nigeria blocks Shell's asset sale in the Niger Delta
Nigeria blocks Shell's asset sale in the Niger Delta
Oct 21, 2024
ABUJA, Oct 21 (Reuters) - Nigeria has blocked the sale of Shell's entire onshore and shallow-water oil and gas assets in the Niger Delta, the country's upstream regulator said on Monday, roughly 10 months after the deal was announced. In a speech at an event in the capital Abuja, Nigerian Upstream Petroleum Regulatory Commission (NUPRC) CEO Gbenga Komolafe said the...
Copyright 2023-2025 - www.financetom.com All Rights Reserved